pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

被引:0
|
作者
Kobayashi, K
Bouscarel, B
Matsuzaki, Y
Ceryak, S
Kudoh, S
Fromm, H
机构
[1] George Washington Univ, Med Ctr, Div Gastroenterol & Nutr, Washington, DC 20037 USA
[2] Nippon Med Sch, Dept Internal Med 4, Tokyo 113, Japan
[3] George Washington Univ, Dept Biochem & Mol Biol, Washington, DC USA
[4] Univ Tsukuba, Div Gastroenterol, Ibaraki, Osaka, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Irinotecan (CPT-11) and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), are believed to be reabsorbed by intestinal cells and to enter the entero-hepatic circulation, but there is little information to date. Our objective was to investigate the intestinal transport of CPT-11 and SN-38 in correlation with their associated cytotoxicity. Using either isolated hamster intestinal epithelial cells or/and human colon carcinoma HT29 cells, the uptake rates of [C-14]CPT-11 and [C-14]SN-38, both as respective non-ionic lactone form at acidic pH and anionic carboxylate form at basic pH, were investigated by the rapid vacuum filtration technique. The effect of physiologic intestinal luminal pH (6.2-8.0) on the uptake rate and cytotoxicity of SN-38 were estimated by the above method and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, respectively. The lactone forms of CPT-11 and SN-38 were transported passively, while the respective carboxylate form was absorbed actively. Uptake rates of both lactones were significantly higher than those of their carboxylates, Under physiologic pH, the respective uptake rates of CPT-11 and SN-38 were pH sensitive and decreased significantly by around 65%, at pH greater than 6.8. Furthermore, with decreasing pH, a higher uptake rate of SN-38 into HT29 cells correlates with a greater cytotoxic effect (r = 0.987). CPT-11 and SN-38 have absorption characteristics of weakly basic drugs such as short-chain fatty acids, suggesting that alkalization of the intestinal lumen may be critical to reduce their reabsorption and associated side effects. Int. J. Cancer 83:491-496, 1999. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:491 / 496
页数:6
相关论文
共 50 条
  • [1] Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
    Kobayashi, K
    Ceryak, S
    Matsuzaki, Y
    Kudoh, S
    Bouscarel, B
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2001, 1525 (1-2): : 125 - 129
  • [2] Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats
    Yamamoto, Michiko
    Kurita, Akinobu
    Asahara, Takashi
    Takakura, Akira
    Katono, Ken
    Iwasaki, Maiko
    Ryuge, Shinichiro
    Wada, Mayuko
    Onoda, Sayaka
    Yanaihara, Tomoko
    Yokoba, Masanori
    Mitsufuji, Hisasht
    Nishji, Yasuto
    Fukui, Tomoya
    Masuda, Noriyuki
    ONCOLOGY REPORTS, 2008, 20 (04) : 727 - 730
  • [3] Development of ELISAs for irinotecan and its active metabolite SN-38
    Saita, T
    Fujito, H
    Mori, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2000, 23 (08) : 911 - 916
  • [4] Uptake mechanism of irinotecan (CPT-11) and its metabolite (SN-38) by hamster intestinal cells.
    Kobayashi, K
    Bouscarel, B
    Matsuzaki, Y
    Ceryak, S
    Fromm, H
    GASTROENTEROLOGY, 1998, 114 (04) : A626 - A627
  • [5] Passage of irinotecan and its active metabolite, SN-38, into human milk
    Nakagawa, J.
    Terui, K.
    Hosoi, K.
    Ueno, K.
    Yokoyama, Y.
    Hayakari, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (05) : 579 - 582
  • [6] Cellular uptake and toxicity of irinotecan and its active metabolite, SN-38 in hamster intestine and human colon cancer cells
    Matsuzaki, Y
    Kobayashi, K
    Bouscarel, B
    Ceryak, S
    Jordan, T
    Fromm, H
    Kudoh, S
    Tanaka, N
    GASTROENTEROLOGY, 1999, 116 (04) : A906 - A906
  • [7] Fasting reduces the systemic exposure to irinotecan and its active metabolite SN-38
    Huisman, Sander A.
    de Bruijn, P.
    Moghaddam-Helmantel, I. M. Ghobadi
    IJzermans, J. N. M.
    Wiemer, E.
    Mathijssen, A. H. J.
    de Bruin, R. W. F.
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2
    Itoh, T
    Itagaki, S
    Sumi, Y
    Hirano, T
    Takemoto, I
    Iseki, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (05) : 420 - 424
  • [9] Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2
    Tatsuya Itoh
    Shirou Itagaki
    Yoshinobu Sumi
    Takeshi Hirano
    Isao Takemoto
    Ken Iseki
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 420 - 424
  • [10] CHARACTERIZATION OF HEPATIC UPTAKE MECHANISM FOR SN-38, AN ACTIVE METABOLITE OF THE ANTICANCER AGENT IRINOTECAN IN HUMANS
    Kato, Yukio
    DRUG METABOLISM REVIEWS, 2012, 44 : 95 - 96